{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:50:11Z","timestamp":1791039011470,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To review the adverse drug reactions (ADRs) of Topiramate and Lamotrigine among children in Israel, and to compare the two drugs, based on their side effect profile and tolerability among this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a cross\u2010sectional study. Four paediatric neurologists from three different tertiary medical centres in Israel documented all cases of children from birth to the age 18 years, treated with Topiramate and\/or Lamotrigine in their respective outpatient clinics and hospital wards. All present ADRs and their characteristics were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Reports on 45 and 65 children treated with Topiramate and Lamotrigine respectively, were received. Half of the children treated with Topiramate suffered from one or more ADRs, as opposed to one\u2010third of the children treated with Lamotrigine (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). Most reactions were considered mild to moderate. There were no deaths or hospitalisations, but the drug had to be discontinued in about 10% of the patients due to ADRs. Most Topiramate and Lamotrigine ADRs appeared early in the treatment and were more frequent when Topiramate was an add\u2010on versus a monotherapy drug. Most ADRs of both Topiramate and Lamotrigine were related to the central nervous system; while poor appetite, drowsiness, speech difficulties and weight loss were observed only with Topiramate, and rash and headaches only with Lamotrigine. Nervousness and seizure aggravation were more frequent ADRs of Topiramate whereas sleep disturbances were observed more in children treated with Lamotrigine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results of this study indicate that Lamotrigine causes ADRs less frequently than Topiramate; however both medications are generally well tolerated. Topiramate and Lamotrigine differ in their central nervous system side effect profile. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1041","type":"journal-article","created":{"date-parts":[[2004,11,13]],"date-time":"2004-11-13T00:49:13Z","timestamp":1100306953000},"page":"187-192","source":"Crossref","is-referenced-by-count":14,"title":["Adverse reactions of Topiramate and Lamotrigine in children"],"prefix":"10.1002","volume":"14","author":[{"given":"Tamar","family":"Shechter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamir","family":"Shorer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tally","family":"Lerman\u2010Sagie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisheva","family":"Ronen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Gorodischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2215"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00001.x"},{"key":"e_1_2_1_4_2","unstructured":"Topiramate (TOPAMAX\u00ae) Product Information. Ortho\u2010McNeil Pharmaceuticals Inc.Raritan NJ 08869 June2003."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(03)00028-7"},{"key":"e_1_2_1_6_2","unstructured":"Ortho\u2010McNeil Pharmaceuticals Inc.Raritan NJ 08869 Important Drug Warning September 26 2001."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.37201.x"},{"key":"e_1_2_1_8_2","unstructured":"Ortho\u2010McNeil Pharmaceuticals Inc.Raritan NJ 08869 Important Drug Warning July2003."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022040-00003"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02445.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380201700408"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(97)80053-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.125256"},{"key":"e_1_2_1_14_2","unstructured":"Lamotrigine (Lamictal\u00ae) product information.Glaxo\u2010 Wellcome Inc.Research Triangle Park NC 27709. November1998."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(99)00106-X"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00254.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.87.6.462"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124070-00004"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1041","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:35:52Z","timestamp":1700188552000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1002\/pds.1041"],"URL":"https:\/\/doi.org\/10.1002\/pds.1041","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}